Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + sargramostim

Development stage: Unknown
Lead developer: Partner Therapeutics
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), and sargramostim (GM-CSF, a colony stimulating factor). Cyclophosphamide and doxorubicin work by damaging DNA in cancer cells, preventing them from dividing and replicating. Sargramostim stimulates the production of white blood cells to counteract chemotherapy-induced neutropenia. This combination is primarily used in the treatment of breast cancer.

Other names: AC with GM-CSF supportFAC with GM-CSF supportCAF with GM-CSF support

Targets

TOP2A (DNA topoisomerase II)DNACSF2R (Granulocyte-macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + sargramostim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + sargramostim.

Explore the full profile